Colloidal aggregates of small molecules are the most common artifact in early drug discovery, sequestering and inhibiting target proteins without specificity. Understanding their structure and mechanism has been crucial to developing tools to control for, and occasionally even exploit, these particles. Unfortunately, their polydispersity and transient stability have prevented exploration of certain elementary properties, such as how they pack. Dye-stabilized colloidal aggregates exhibit enhanced homogeneity and stability when compared to conventional colloidal aggregates, enabling investigation of some of these properties. By small-angle X-ray scattering and multiangle light scattering, pair distance distribution functions suggest that the ...
Programmable colloidal assembly enables the creation of mesoscale materials in a bottom-up manner. A...
Many amyloid proteins form metastable soluble aggregates (or protofibrils, or protein nanoparticles,...
Small molecule effectors are essential for drug discovery. Specific molecular recognition, reversibl...
Colloidal aggregates of small molecules are the most common artifact in early drug discovery, seques...
Small molecule aggregates are considered nuisance compounds in drug discovery, but their unusual pro...
Small molecule aggregates are considered nuisance compounds in drug discovery, but their unusual pro...
Colloidal aggregation presents a significant nuisance in drug discovery programs; the self-assembly ...
Small molecule colloidal aggregates adsorb and partially denature proteins, inhibiting them artifact...
Looking at globular proteins with the eyes of a colloid scientist has a long tradition, in fact a si...
Small-molecule aggregates are a leading cause of artifacts in early drug discovery, but little is kn...
The recent high-resolution structures of amyloid fibrils show that the organization of peptide segme...
The need for a better understanding of nanoparticle–protein interactions and the mechanisms governin...
Early drug discovery is plagued by nonspecific molecules, which cannot be developed into drugs. Thes...
Many small molecules, including bioactive molecules and approved drugs, spontaneously form colloidal...
International audienceCoupling a hydrophobic drug onto monoclonal antibodies via lysine residues is ...
Programmable colloidal assembly enables the creation of mesoscale materials in a bottom-up manner. A...
Many amyloid proteins form metastable soluble aggregates (or protofibrils, or protein nanoparticles,...
Small molecule effectors are essential for drug discovery. Specific molecular recognition, reversibl...
Colloidal aggregates of small molecules are the most common artifact in early drug discovery, seques...
Small molecule aggregates are considered nuisance compounds in drug discovery, but their unusual pro...
Small molecule aggregates are considered nuisance compounds in drug discovery, but their unusual pro...
Colloidal aggregation presents a significant nuisance in drug discovery programs; the self-assembly ...
Small molecule colloidal aggregates adsorb and partially denature proteins, inhibiting them artifact...
Looking at globular proteins with the eyes of a colloid scientist has a long tradition, in fact a si...
Small-molecule aggregates are a leading cause of artifacts in early drug discovery, but little is kn...
The recent high-resolution structures of amyloid fibrils show that the organization of peptide segme...
The need for a better understanding of nanoparticle–protein interactions and the mechanisms governin...
Early drug discovery is plagued by nonspecific molecules, which cannot be developed into drugs. Thes...
Many small molecules, including bioactive molecules and approved drugs, spontaneously form colloidal...
International audienceCoupling a hydrophobic drug onto monoclonal antibodies via lysine residues is ...
Programmable colloidal assembly enables the creation of mesoscale materials in a bottom-up manner. A...
Many amyloid proteins form metastable soluble aggregates (or protofibrils, or protein nanoparticles,...
Small molecule effectors are essential for drug discovery. Specific molecular recognition, reversibl...